ARTV vs IPSC
ARTV: Artiva Biotherapeutics is developing off-the-shelf, allogeneic NK cell therapies designed to address B-cell driven autoimmune diseases through enhanced antibody-dependent cellular cytotoxicity. IPSC: Century Therapeutics is pioneering scalable, off-the-shelf allogeneic cell therapies using an iPSC-derived platform to treat autoimmune diseases and cancer.
Side-by-side fundamentals
| Metric | ARTV | IPSC | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $6.49 | $1.61 | |
| Market cap | $317M | $292M | |
| Net margin FY2025, SEC XBRL | n/a | -8.8% | |
| Operating margin FY2025, SEC XBRL | n/a | -15.8% | |
| ROE FY2025, SEC XBRL | -76.3% | -6.0% | IPSC higher |
| ROA FY2025, SEC XBRL | -64.0% | -4.3% | IPSC higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +1556.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +175.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.57 | 1.50 | |
| 1-year return as of 2026-10-21 close | +48.9% | +185.0% | IPSC higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.